World's Best Scientists 2026 revealed!

Henk M. Lokhorst publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Henk M. Lokhorst sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

Henk M. Lokhorst D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Henk M. Lokhorst sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

Henk M. Lokhorst is affiliated with VU University Medical Center in the Netherlands. Their research primarily spans the fields of Biochemistry, Genetics, and Molecular Biology, as well as Medicine. Within these disciplines, Lokhorst's work focuses on several subfields, including Molecular Biology, Cancer Research, Hematology, and Genetics.

Their research contributions cover a variety of topics related to cancer and hematological diseases. Key research areas include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Cancer-related Molecular Mechanisms, Cancer Genomics and Diagnostics, Extracellular Vesicles in Disease, PI3K/AKT/mTOR Signaling in Cancer, and Myeloproliferative Neoplasms Diagnosis and Treatment.

Lokhorst has coauthored multiple scientific papers with frequent collaborators such as Thomas Hielscher, Hans Salwender, Peter Brossart, Marc S. Raab, and Jens Hillengaß.

The scientist has published articles in several peer-reviewed journals, including Cancer Cell, Blood Cancer Journal, and HemaSphere. Notable recent publications include:

  • Detection and localization of early- and late-stage cancers using platelet RNA, 2022, Cancer Cell
  • Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma, 2021, Blood Cancer Journal
  • Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial, 2024, HemaSphere

Best Publications

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Targeting CD38 with daratumumab monotherapy in multiple myeloma

    Henk M Lokhorst;Torben Plesner;Jacob P Laubach;Hareth Nahi

  • Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors

    Michel De Weers;Yu Tzu Tai;Michael S. Van Der Veer;Joost M. Bakker

  • Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

    Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari

  • Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

    Jakub Krejcik;Jakub Krejcik;Tineke Casneuf;Inger S. Nijhof;Bie Verbist

  • Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

    Saad Z. Usmani;Brendan M. Weiss;Torben Plesner;Nizar J. Bahlis

  • Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

    Kai Neben;Henk M. Lokhorst;Anna Jauch;Uta Bertsch

  • Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

    Antonio Palumbo;Sara Bringhen;Heinz Ludwig;Meletios A. Dimopoulos

  • International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.

    M Dimopoulos;E Terpos;R L Comenzo;P Tosi

  • Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term Outcome

    H.M. Lokhorst;A. Schattenberg;J.J. Cornelissen;M.H. J. van Oers

  • Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

    Annemiek Broyl;Dirk Hose;Henk Lokhorst;Yvonne de Knegt

  • Illegitimate WNT signaling promotes proliferation of multiple myeloma cells

    Patrick W. B. Derksen;Esther Tjin;Helen P. Meijer;Melanie D. Klok

  • CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

    Inger S. Nijhof;Inger S. Nijhof;Tineke Casneuf;Jeroen van Velzen;Berris van Kessel

  • A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

    Henk M. Lokhorst;Bronno van der Holt;Sonja Zweegman;Edo Vellenga

  • Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

    Niels W. C. J. van de Donk;Maarten L. Janmaat;Tuna Mutis;Jeroen J. Lammerts van Bueren

  • Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study

    Pierre Wijermans;Martijn Schaafsma;Fabian Termorshuizen;Rianne Ammerlaan

  • Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

    Pieter Sonneveld;Hartmut Goldschmidt;Laura Rosiñol;Joan Bladé

  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    S. K. Kumar;M. A. Dimopoulos;E. Kastritis;E. Terpos

  • Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

    Annemiek Broyl;Sophie L. Corthals;Joost L. M. Jongen;Bronno van der Holt

  • Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

    Shaji Kumar;Meletios A Dimopoulos;Efstathios Kastritis;Evangelos Terpos

Frequent Co-Authors

Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Tuna Mutis
Tuna Mutis Vrije Universiteit Amsterdam
Sonja Zweegman
Sonja Zweegman Amsterdam UMC
Sagar Lonial
Sagar Lonial Emory University
Antonio Palumbo
Antonio Palumbo University of Turin
Hartmut Goldschmidt
Hartmut Goldschmidt University Hospital Heidelberg
Saad Z. Usmani
Saad Z. Usmani Memorial Sloan Kettering Cancer Center
Paul W. H. I. Parren
Paul W. H. I. Parren Leiden University Medical Center
Edo Vellenga
Edo Vellenga University Medical Center Groningen
Michele Cavo
Michele Cavo University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in Medicine goes beyond becoming a doctor. Today, there are numerous accessible online degree paths in healthcare. For those interested in managing patient records and information, rhit programs online offer a flexible way to gain certification in health information management.

If you want to enter the medical billing or coding sector, you can benefit from the cheapest medical coding certification online. These programs help you quickly qualify for essential support roles in healthcare facilities.

Aspiring advanced care providers can explore the cheapest online acute care nurse practitioner programs to build specialized skills and expand patient care responsibilities.

For those starting their nursing journey, nursing school online options are available, making it possible to study from home and achieve RN or BSN credentials.

Each of these online pathways offers affordable and convenient entry points into the expanding healthcare workforce, making them attractive options for students seeking flexibility and growth in their medical careers.

Best Scientists Citing Henk M. Lokhorst

Trending Scientists